Drugs / IEV407
last change May 2026 re-read 2 minutes ago

IEV407

Developed for
hormone receptor-positive breast cancer
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07604571 May 2026 → Jun 2032 expected hormone receptor-positive breast cancer Novartis Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IEV407 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07604571